Management

THPX05_About_72dpi_1575x325_170517

About

Therapix is building a specialty pharma­ceu­tical company focused on signif­i­cantly enhancing FDA-approved dronabinol for the treat­ment of Tourette Syndrome and Mild Cognitive Impairment.

Dr. Ascher Shmulewitz, MD, PhD

Interim Chief Executive Officer

Chairman of Therapix’s Board of Directors since January 2014, Dr. Shmulewitz has also served as a Board member since February 2013. With doctorate degrees in medicine and engineering, Dr. Shmulewitz spent much of his career as a successful inventor, investor and serial entre­pre­neur in the biomed­ical technolo­gies field, facil­i­tating a wide range of corpo­rate collab­o­ra­tions. He founded and invested in over twenty-four life science compa­nies – many of which enjoyed successful exits via merger & acqui­si­tion trans­ac­tions with large medical device compa­nies – including Arteria Corp., Circulation Inc., Labcoat Medical Ltd., NeoVision Corp, and X-Cardia Inc. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group which both provide seed funding to promising compa­nies. He also founded the private Israeli invest­ment firm and incubator Medgenesis Partners Ltd. which has invested in over a dozen ventures. Between 1988 and 1992, Dr. Shmulewitz held senior execu­tive positions at Advanced Technology Laboratories Inc.. He received his M.D. from The Technion Medical School, and a Ph.D. in Engineering from Tel Aviv University, Israel.

JOSH BLACHER

Chief Financial Officer

Mr. Blacher joined Therapix in 2017 bringing with him more than nine years of experi­ence in biotech-related finan­cial manage­ment, including as a CFO of a NASDAQ-traded company, business devel­op­ment, investing and opera­tions, as well as 14 years in capital markets. Prior to joining Therapix, Mr. Blacher was the CFO for Galmed Pharmaceuticals, and earlier served as Director of Business Development at Teva Innovative Ventures, Teva Pharmaceuticals’ early- and mid-stage invest­ment and in-licensing arm. In that capacity, Mr. Blacher helped build and manage Teva’s portfolio of approx­i­mately 20 equity invest­ments in biotech entities, spanning a wide range of devel­op­ment stage compa­nies from pre-clinical through Phase III projects, and various thera­peutic areas. Mr. Blacher also held positions in portfolio manage­ment at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acqui­si­tions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.

DR. ADI ZULOFF-SHANI, PhD

Chief Technology Officer

Dr. Adi Zuloff-Shani has served as Chief Technologies Officer at Therapix since February 2016, bringing with her more than 15 years of experi­ence as an R&D execu­tive. From 2012 until 2016, Dr. Zuloff–Shani served as a Vice President of Development at Macrocure Ltd. (NASDAQ: “MCUR”) where, aside from leading all research and devel­op­ment activ­i­ties, she inter­acted, and was involved, with the activ­i­ties of all depart­ments including clinical, opera­tions, quality assur­ance, quality control, finance, and regula­tory affairs. Prior to that, Dr. Zuloff-Shani spent eight years as the Senior Scientist in the Research & Development Unit of Magen David Adom’s National Blood Services. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.

DORON BEN AMI

Chief Strategy Officer

Mr. Doron Ben Ami has been Therapix’s Chief Strategy Officer since December 2015. A seasoned execu­tive with more than 20 years of manage­ment experi­ence, he has held various leader­ship roles in the multi­na­tional pharma­ceu­tical industry. Mr. Ben Ami previ­ously held a range of execu­tive positions including Associate Vice President for the Eastern European and Israel region at Merck (from 2010 to 2015), Managing Director of the Merck subsidiary in Israel (from 2008 to 2010), and General Manager of Lundbeck Israel (from 2002 to 2008). Since 2015, Mr. Ben Ami has served as a Senior Consultant at The Harel Group Inc., a U.S. based business devel­op­ment advisory firm that connects innov­a­tive pharma­ceu­tical compa­nies with strategic partners. Mr. Ben Ami holds a Master of Health Systems Administration degree (M.H.A.) from Tel Aviv University, Israel.